Figure 3.

Overexpression of RHPN1-AS1 confers gefitinib sensitive to NSCLC cells. (A) qRT-PCR analysis of RHPN1-AS1 in PC9GR (left) and HCC827GR (right) cells transfected with pcDNA-Control or pcDNA-RHPN1-AS1 for 48h; (B) Determination of gefitinib IC₅₀ in PC9GR (left) and HCC827GR (right) cells transfected with pcDNA-Control or pcDNA-RHPN1-AS1 for 24h; (C) Flow cytometry analysis of apoptosis in PC9GR and HCC827GR cells transfected with pcDNA-Control or pcDNA-RHPN1-AS1 prior to the stimulation of 0.1 μM gefitinib treatment for 36h; (D) Transwell migration assay of PC9GR and HCC827GR cells pretreated with pcDNA-Control or pcDNA-RHPN1-AS1 6h prior to the stimulation with 0.1 μM gefitinib for 24h; (E) Tumor xenografts were established in nude mice by subcutaneously injection of PC9GR-LV-Control cells or PC9GR-LV-RHPN1-AS1 cells for 14 days and then treated with treatment gefitinib (20 mg/kg/d) or PBS containing 1% Tween 80 control, tumor volume was determined every 5 days after the onset of treatment, scale bar = 1 cm. Data are presented as the mean ± SD. (*P < 0.05, **P < 0.01, ***P < 0.001).